CL2013001391A1 - Enantiomeros 2r y 2s de dodecil 2-(n,n-dimetilamino)-propionato con una pureza enantiomerica de al menos 70%, sus sales; y metodo para facilitar el transporte de un compuesto activo tal como lansoprazol a traves de una membrana o tejido biologico en la presencia de 2r-dodecil 2-(n,n-dimetilamino)-propionato. - Google Patents
Enantiomeros 2r y 2s de dodecil 2-(n,n-dimetilamino)-propionato con una pureza enantiomerica de al menos 70%, sus sales; y metodo para facilitar el transporte de un compuesto activo tal como lansoprazol a traves de una membrana o tejido biologico en la presencia de 2r-dodecil 2-(n,n-dimetilamino)-propionato.Info
- Publication number
- CL2013001391A1 CL2013001391A1 CL2013001391A CL2013001391A CL2013001391A1 CL 2013001391 A1 CL2013001391 A1 CL 2013001391A1 CL 2013001391 A CL2013001391 A CL 2013001391A CL 2013001391 A CL2013001391 A CL 2013001391A CL 2013001391 A1 CL2013001391 A1 CL 2013001391A1
- Authority
- CL
- Chile
- Prior art keywords
- dimethylamino
- propionate
- dodecyl
- lansoprazole
- enantiomers
- Prior art date
Links
- -1 2-dodecyl Chemical group 0.000 title 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 title 1
- HSMMSDWNEJLVRY-INIZCTEOSA-N dodecyl (2s)-2-(dimethylamino)propanoate Chemical compound CCCCCCCCCCCCOC(=O)[C@H](C)N(C)C HSMMSDWNEJLVRY-INIZCTEOSA-N 0.000 title 1
- MJIHNNLFOKEZEW-UHFFFAOYSA-N lansoprazole Chemical compound CC1=C(OCC(F)(F)F)C=CN=C1CS(=O)C1=NC2=CC=CC=C2N1 MJIHNNLFOKEZEW-UHFFFAOYSA-N 0.000 title 1
- 229960003174 lansoprazole Drugs 0.000 title 1
- 239000012528 membrane Substances 0.000 title 1
- 150000003839 salts Chemical class 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/221—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having an amino group, e.g. acetylcholine, acetylcarnitine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
- C07C229/06—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Emergency Medicine (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US41899610P | 2010-12-02 | 2010-12-02 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2013001391A1 true CL2013001391A1 (es) | 2013-11-08 |
Family
ID=46172526
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2013001391A CL2013001391A1 (es) | 2010-12-02 | 2013-05-16 | Enantiomeros 2r y 2s de dodecil 2-(n,n-dimetilamino)-propionato con una pureza enantiomerica de al menos 70%, sus sales; y metodo para facilitar el transporte de un compuesto activo tal como lansoprazol a traves de una membrana o tejido biologico en la presencia de 2r-dodecil 2-(n,n-dimetilamino)-propionato. |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US20130267562A1 (enExample) |
| EP (1) | EP2646015B1 (enExample) |
| JP (1) | JP6109075B2 (enExample) |
| KR (1) | KR102004552B1 (enExample) |
| CN (1) | CN103930105B (enExample) |
| AU (2) | AU2011336692B2 (enExample) |
| BR (1) | BR112013012799A8 (enExample) |
| CA (1) | CA2817417C (enExample) |
| CL (1) | CL2013001391A1 (enExample) |
| CR (1) | CR20130324A (enExample) |
| ES (1) | ES2801999T3 (enExample) |
| IL (1) | IL226173A (enExample) |
| MX (1) | MX2013005522A (enExample) |
| NZ (1) | NZ609826A (enExample) |
| PH (1) | PH12013501104A1 (enExample) |
| PL (1) | PL2646015T3 (enExample) |
| RU (1) | RU2679308C2 (enExample) |
| SG (2) | SG10201803321TA (enExample) |
| WO (1) | WO2012075107A2 (enExample) |
| ZA (1) | ZA201304840B (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014028780A2 (en) * | 2012-08-15 | 2014-02-20 | Nexmed Holdings, Inc. | Antifungal compounds and methods of use |
| US8900625B2 (en) | 2012-12-15 | 2014-12-02 | Nexmed Holdings, Inc. | Antimicrobial compounds and methods of use |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6118020A (en) * | 1999-05-19 | 2000-09-12 | Nexmed Holdings, Inc. | Crystalline salts of dodecyl 2-(N,N-dimethylamino)-propionate |
| US6323241B1 (en) * | 2000-01-10 | 2001-11-27 | Nexmed (Holdings) Inc. | Prostaglandin compositions and methods of treatment for male erectile dysfunction |
| DE10033853A1 (de) * | 2000-07-12 | 2002-01-31 | Hexal Ag | Transdermales therapeutisches System mit hochdispersem Siliziumdioxid |
| JP5160018B2 (ja) * | 2002-06-25 | 2013-03-13 | アクルックス・ディ・ディ・エス・プロプライエタリー・リミテッド | 非晶質医薬組成物を用いる経皮送達速度調節 |
| US20050181030A1 (en) * | 2003-01-03 | 2005-08-18 | Mo Y. J. | Topical stabilized prostaglandin E compound dosage forms |
| EP1635770B1 (en) * | 2003-03-21 | 2009-05-27 | Nexmed Holdings, Inc. | Antifungal nail coat and method of use |
| WO2005009510A2 (en) * | 2003-07-23 | 2005-02-03 | The Regents Of The University Of California | Penetration enhancer combinations for transdermal delivery |
| PL1670433T3 (pl) * | 2003-10-10 | 2013-03-29 | Ferring Bv | Przezskórna formulacja farmaceutyczna do zmniejszania pozostałości na skórze |
| WO2005051960A2 (en) * | 2003-11-22 | 2005-06-09 | Midwest Research Laboratories, Llc | Hydrocarbyl aminohydrocarbonoates and aminohydrocarbonol hydrocarbonoates as antimicrobial and antiviral agents |
| RU2012153177A (ru) * | 2010-05-04 | 2014-06-20 | Нексмед Холдингс, Инк. | Композиции низкомолекулярных терапевтических средств |
| US8900625B2 (en) * | 2012-12-15 | 2014-12-02 | Nexmed Holdings, Inc. | Antimicrobial compounds and methods of use |
-
2011
- 2011-11-30 NZ NZ609826A patent/NZ609826A/en not_active IP Right Cessation
- 2011-11-30 KR KR1020137013227A patent/KR102004552B1/ko not_active Expired - Fee Related
- 2011-11-30 MX MX2013005522A patent/MX2013005522A/es unknown
- 2011-11-30 JP JP2013542128A patent/JP6109075B2/ja not_active Expired - Fee Related
- 2011-11-30 PL PL11845087T patent/PL2646015T3/pl unknown
- 2011-11-30 PH PH1/2013/501104A patent/PH12013501104A1/en unknown
- 2011-11-30 US US13/991,111 patent/US20130267562A1/en not_active Abandoned
- 2011-11-30 EP EP11845087.3A patent/EP2646015B1/en active Active
- 2011-11-30 CA CA2817417A patent/CA2817417C/en not_active Expired - Fee Related
- 2011-11-30 AU AU2011336692A patent/AU2011336692B2/en not_active Ceased
- 2011-11-30 WO PCT/US2011/062579 patent/WO2012075107A2/en not_active Ceased
- 2011-11-30 SG SG10201803321TA patent/SG10201803321TA/en unknown
- 2011-11-30 SG SG2013035258A patent/SG190199A1/en unknown
- 2011-11-30 ES ES11845087T patent/ES2801999T3/es active Active
- 2011-11-30 CN CN201180054224.5A patent/CN103930105B/zh not_active Expired - Fee Related
- 2011-11-30 RU RU2013119439A patent/RU2679308C2/ru not_active Application Discontinuation
- 2011-11-30 BR BR112013012799A patent/BR112013012799A8/pt not_active Application Discontinuation
-
2013
- 2013-05-05 IL IL226173A patent/IL226173A/en active IP Right Grant
- 2013-05-16 CL CL2013001391A patent/CL2013001391A1/es unknown
- 2013-06-26 CR CR20130324A patent/CR20130324A/es unknown
- 2013-06-28 ZA ZA2013/04840A patent/ZA201304840B/en unknown
-
2017
- 2017-01-17 AU AU2017200314A patent/AU2017200314A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| SG10201803321TA (en) | 2018-06-28 |
| ES2801999T3 (es) | 2021-01-15 |
| BR112013012799A8 (pt) | 2018-01-09 |
| CN103930105A (zh) | 2014-07-16 |
| AU2011336692B2 (en) | 2017-02-16 |
| KR20140023875A (ko) | 2014-02-27 |
| AU2017200314A1 (en) | 2017-02-02 |
| MX2013005522A (es) | 2013-07-17 |
| CA2817417C (en) | 2020-12-29 |
| SG190199A1 (en) | 2013-06-28 |
| US20130267562A1 (en) | 2013-10-10 |
| KR102004552B1 (ko) | 2019-10-01 |
| PL2646015T3 (pl) | 2020-11-30 |
| EP2646015A2 (en) | 2013-10-09 |
| RU2679308C2 (ru) | 2019-02-07 |
| CR20130324A (es) | 2013-08-13 |
| BR112013012799A2 (pt) | 2016-09-13 |
| WO2012075107A2 (en) | 2012-06-07 |
| CN103930105B (zh) | 2019-11-01 |
| WO2012075107A3 (en) | 2014-03-06 |
| RU2013119439A (ru) | 2015-01-10 |
| JP6109075B2 (ja) | 2017-04-05 |
| IL226173A (en) | 2016-10-31 |
| NZ609826A (en) | 2016-03-31 |
| JP2014514243A (ja) | 2014-06-19 |
| ZA201304840B (en) | 2014-04-30 |
| EP2646015A4 (en) | 2015-04-08 |
| EP2646015B1 (en) | 2020-04-22 |
| AU2011336692A1 (en) | 2013-05-30 |
| IL226173A0 (en) | 2013-07-31 |
| PH12013501104A1 (en) | 2013-07-08 |
| CA2817417A1 (en) | 2012-06-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2613674T3 (es) | Uso del organismo fúngico Pythium oligandrum | |
| CL2014003475A1 (es) | Forma c cristalina de acido obeticolico; proceso de preparacion de la forma 1 de acido obeticolico a partir de la forma c cristalina; composicion farmaceutica que comprende a una forma cristalina de acido obeticolico, util para el tratamiento o prevencion de una enfermedad hepatica colestasica, hepatopatia alcoholica y enfermedades cardiovasculares tal como aterosclerosis, entre otras. | |
| SI3590949T1 (sl) | Ribonukleinske kisline, ki vsebujejo N1-metil-psevdouracil, in njihove uporabe | |
| CL2014001162A1 (es) | Inoculantes microbianos que comprenden lactobacillus; composicion fertilizante que comprenden los mismos; metodo para aumentar crecimiento y/o la productividad de plantas. | |
| CL2014002855A1 (es) | Corral para peces para evitar el estrés de los peces durante el proceso de cosecha y traspaso, comprende una pared que define una vía serpenteante hacia adentro a lo largo de la cual los peces viajan; acumulador de peces para distribuir los peces; disposición que comprende un corral para peces. | |
| CL2014002906A1 (es) | Un metodo para la preparacion de 2-(2,3-dimetilfenil)-1-propanal a partir de 1-bromo-2,3-dimetilbenceno y cloroacetona, util en perfumes y en la preparacion de medetomidina. | |
| IT1401527B1 (it) | Macchina etichettatrice, particolarmente per l'etichettatura di contenitori. | |
| BR112013004409A8 (pt) | recipiente para armazenar artigos para cuidados pessoais. | |
| CL2014000645A1 (es) | Composicion farmaceutica que comprende a) un ciclopolisacarido tal como una ciclodextrina y b) un compuesto derivado de acido hidroxamico y sus sales, util para tratar una enfermedad neoplasica o una enfermedad inmunitaria. | |
| BR112014026149A2 (pt) | método para a preparação de 2,4-ácido dihidroxibutírico (2,4-dhb) e microrganismo. | |
| CL2013002338A1 (es) | Un sistema que comprende: una herramienta electrostatica configurado para entregar una descarga para matar a una celula biologica, en el que la herramienta electrostatica comprende: un aplicador electrostatico configurado para emitir un campo electrostatico en el que la descarga comprende el campo electrostatico. | |
| CL2013000735A1 (es) | Uso de una composicion que comprende compuestos derivados de 1-h-imidazol-4-il sustituido para el tratamiento de enfermedades y condiciones de la piel, tales como rosacea, daño solar cronico, psoriasis, entre otras; kit farmaceutico. | |
| IT1398969B1 (it) | Dispositivo di alimentazione di anime in una macchina ribobinatrice per la produzione di rotoli. | |
| BR112013022556A2 (pt) | composição farmacêutica aquosa semissólida contendo tapentadol | |
| CL2013001391A1 (es) | Enantiomeros 2r y 2s de dodecil 2-(n,n-dimetilamino)-propionato con una pureza enantiomerica de al menos 70%, sus sales; y metodo para facilitar el transporte de un compuesto activo tal como lansoprazol a traves de una membrana o tejido biologico en la presencia de 2r-dodecil 2-(n,n-dimetilamino)-propionato. | |
| PL2240486T3 (pl) | Sole triazoliowe jako inhibitory PAR1, ich wytwarzanie i zastosowanie jako lek | |
| CL2013000291A1 (es) | Método para envasar esporas fúngicas que comprende reducir la actividad acuosa inicial de las esporas a menos de 0,3, colocar las esporas denrto de un envase impermeable al vapor de agua y mantener las esporas en el envasado durante al menos dos días a temperaturas entre 15 y 25 grados celcius. | |
| FR2943896B1 (fr) | "roll-on" a forte teneur en acide salicylique. | |
| IT1398335B1 (it) | Impianto per lo stoccaggio di prodotti. | |
| CL2014002728A1 (es) | Composicion farmaceutica que comprende un agente reductor de urato que es un compuesto fenil-metil-fenoxi sustituido tal como halofenato, acido halofenico o sus sales y un agente antiinflamatorio tal como colquicina; kit que comprende dicha composicion; y metodo para tratar una erupcion de gota y la hiperuricemia en la gota. | |
| ITTO20120262A1 (it) | Impianto per la stampa di nastri di tessuto. | |
| CL2013002041A1 (es) | Metodo para controlar hongos fitopatogenos; uso de una sal potásica del ácido fosfórico porque sirve para aumentar la eficacia del ditianon; composicion que comprende sal potásica del ácido fosfórico y ditianon. | |
| BR112013019996A2 (pt) | Compostos de ácido [(5h-pirrol[2,1-c][1,4] benzodiazepin-11-il)piperazin-1-il]-2,2- dimetilpropanoico substituído com atividade dupla agonistas inversos de h1/antagonistas de 5-ht2a. | |
| BR112012000294A2 (pt) | preparação cosmética contendo ácido glicirretínico. | |
| IT1400800B1 (it) | Sistema biocompatibile di supporto per la piantumazione di organismi vegetali in ambiente marino. |